Question 1

What does STAT3 do in cancer?

Accepted Answer

Constitutively activated STAT3 (typically phosphorylated at Y705 by JAK kinases) drives expression of anti-apoptotic proteins (BCL-XL, MCL1), proliferation genes (cyclin D1), and immunosuppressive cytokines (IL-10, TGF-β). This dual role — promoting tumour cell survival and suppressing anti-tumour immunity — makes STAT3 a central oncogenic hub.

Question 2

How is STAT3 abnormally activated in cancer?

Accepted Answer

STAT3 is constitutively activated by upstream IL-6 receptor/JAK2 signalling in ~70% of haematological malignancies, by oncogenic fusions (EML4-ALK, BCR-ABL), and by activating JAK1/JAK2/STAT3 mutations in T-cell lymphomas. Autocrine cytokine loops and loss of negative regulators (SOCS proteins) also maintain constitutive activation.

Question 3

Are there drugs that target STAT3?

Accepted Answer

JAK inhibitors (ruxolitinib, tofacitinib) suppress upstream JAK-STAT3 signalling and are approved in myeloproliferative neoplasms and inflammatory disorders. Direct STAT3 inhibitors targeting the SH2 domain are in early clinical development. The large protein-protein interaction surface of STAT3 has historically made direct inhibition difficult.

STAT3 Gene Function

Overview

More Oncogenes